Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

(RTTNews) - While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2022, due primarily to headwinds associated with the CDMO business, foreign exchange, and interest expense due to the rising interest rate environment.

For fiscal 2022, the company continues to projects earnings in the range of $7.90 to $8.15 per share and adjusted earnings in the range of $10.70 to $10.95 per share on revenues growth of 9 to 11 percent and organic revenues growth of 10 to 12 percent.

Previously, the company expected earnings in the range of $8.70 to $8.95 per share and adjusted earnings in the range of $11.50 to $11.75 per share on revenues growth of 13.5 to 15.5 percent and organic revenues growth of 12.5 to 14.5 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $11.53 per share on revenue growth of 13.30 percent to $4.01 billion for the year. Analysts' estimates typically exclude special items.

For the second quarter, the company reported the net income attributable to common shareholders of $109.32 million or $2.13 per share, higher than $88.45 million or $1.72 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter was $2.77 per share, compared to $2.61 per share in the year-ago quarter.

Total revenue for the quarter increased 6.4 percent to $973.13 million from $914.61 million in the same quarter last year. Organic revenue growth was 9.5 percent.

The Street was looking for earnings of $2.74 per share on revenues of $994.91 million for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com